MNKD
MannKind Corporation · Healthcare
Insiders bought $259K of MannKind Corporation in the last 12 months
1 insider bought on 1 day.
MNKD over the last year
Largest buyers, last 12 months
MNKD after insider buys
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
46 insider filings since 2017, newest first
Steven B. Binder · Director
Steven B. Binder · Director
Steven B. Binder · Director
David Thomson · EVP Genl Counsel & Secretary
Steven B. Binder · Director
Steven B. Binder · Director
Michael Castagna · CEO
Stuart A Tross · Chief People, Workpl Officer
Michael Castagna · CEO
Michael Castagna · CEO
Michael Castagna · CEO
David Thomson · EVP Genl Counsel, Secretary
Steven B. Binder · Director
Steven B. Binder · Director
Stuart A Tross · Chief People, Workpl Officer
Stuart A Tross · Chief People, Workpl Officer
Stuart A Tross · Chief People, Workpl Officer
Michael Castagna · CEO
Steven B. Binder · EVP Special Projects
David Thomson · EVP Genl Counsel, Secretary
David Thomson · EVP Genl Counsel, Secretary
Steven B. Binder · EVP Special Projects
Michael Castagna · CEO
Michael Castagna · CEO
Michael Castagna · CEO
Michael Castagna · CEO
David Thomson · EVP Genl Counsel, Secretary
Michael Castagna · CEO
Michael Castagna · CEO
Michael Castagna · CEO
Michael Castagna · CEO
Michael Castagna · CEO
David Thomson · EVP Genl Counsel, Secretary
Steven B. Binder · CFO
Michael Castagna · CEO
Michael Castagna · CEO
Michael Castagna · CEO
David Thomson · EVP Genl Counsel, Secretary
Alejandro Galindo · Chief Commercial Officer
Anthony C Hooper · Director
Christine Mundkur · Director
Alejandro Galindo · Chief Commercial Officer
Alejandro Galindo · Chief Commercial Officer
Michael Castagna · CEO
Stuart A Tross · Corp VP, Chief People Officer
Kent Kresa · Director
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.